Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in Gain Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +2 vs. Q1 2023
- Shares held
- 1.27M
- +118.2K (+10.3%) vs. Q1 2023
- Total value
- $5.68M
- +$134.4K (+2.4%) vs. Q1 2023
- New holders
- 4
- 11 more added
- Sold out
- 2
- 3 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GANX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 50 | $17.4M |
| Q1 2026 | 42 | $15.8M |
| Q4 2025 | 48 | $25.9M |
| Q3 2025 | 38 | $7.70M |
| Q2 2025 | 35 | $6.49M |
| Q1 2025 | 33 | $5.07M |
| Q4 2024 | 25 | $3.94M |
| Q3 2024 | 19 | $2.40M |
| Q2 2024 | 28 | $3.89M |
| Q1 2024 | 26 | $7.04M |
| Q4 2023 | 24 | $5.05M |
| Q3 2023 | 24 | $4.95M |
| Q2 2023 | 24 | $5.68M |
| Q1 2023 | 22 | $5.54M |
| Q4 2022 | 21 | $3.78M |
| Q3 2022 | 23 | $3.95M |
| Q2 2022 | 16 | $3.87M |
| Q1 2022 | 16 | $4.75M |
| Q4 2021 | 19 | $5.71M |
| Q3 2021 | 14 | $6.65M |
| Q2 2021 | 14 | $8.95M |
| Q1 2021 | 12 | $15.0M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Gain Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 6 | $27 | 0.00% | +6 | New |
| Morgan Stanley | 800 | $3.58K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 847 | $3.79K | 0.00% | +847 | New |
| HM Payson & Co | 1,000 | $4.48K | 0.00% | +1,000 | New |
| Wells Fargo & Company | 3,718 | $16.7K | 0.00% | +5+0.1% | Added |
| Tower Research Capital LLC (TRC) | 4,347 | $19.5K | 0.00% | −2,497−36.5% | Reduced |
| UBS Group AG | 9,447 | $42.3K | 0.00% | +5,142+119.4% | Added |
| Advisor Group Holdings, Inc. | 10,000 | $44.8K | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 11,050 | $49.5K | 0.00% | +550+5.2% | Added |
| Millennium Management LLC | 12,562 | $56.3K | 0.00% | +12,562 | New |
| Northern Trust Corp | 13,277 | $59.5K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 20,046 | $90.0K | 0.00% | −18,954−48.6% | Reduced |
| Dimensional Fund Advisors LP | 20,962 | $93.9K | 0.00% | +2,355+12.7% | Added |
| BlackRock Inc. | 29,024 | $130.0K | 0.00% | +4,246+17.1% | Added |
| Raymond James & Associates | 33,400 | $149.6K | 0.00% | +13,400+67.0% | Added |
| Citadel Advisors LLC | 36,247 | $162.4K | 0.00% | +18,800+107.8% | Added |
| Bridgeway Capital Management, LLC | 46,100 | $206.5K | 0.00% | −13,900−23.2% | Reduced |
| Renaissance Technologies LLC | 47,600 | $213.0K | 0.00% | +8,900+23.0% | Added |
| Prelude Capital Management, LLC | 58,100 | $260.3K | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 64,118 | $287.2K | 0.00% | +11,513+21.9% | Added |
| Susquehanna International Group, LLP | 69,790 | $312.7K | 0.00% | +54,618+360.0% | Added |
| CM Management, LLC | 90,000 | $403.0K | 0.39% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 138,721 | $621.5K | 0.00% | +44,514+47.3% | Added |
| Greenlight Capital Inc | 546,560 | $2.45M | 0.11% | 00.0% | Unchanged |
| Wealth Alliance Advisory Group, LLC | 0 | $0 | 0.00% | −12,502−100.0% | Sold out |
| Cannell Capital LLC | 0 | $0 | 0.00% | −12,371−100.0% | Sold out |